Explore
Therapeutic Potential for Cannabis and Cannabinoids
0 Ungluers have
Faved this Work
Login to Fave
Cannabis has a history of medical use dating back millennia; however, the use of cannabis for medicinal purposes fell out of favor in the middle of the last century. There is currently a renewed interest in the potential medicinal value of this plant, as well as individual compounds produced by Cannabis (as well as synthetic analogs). Currently, nearly 50 countries permit the medical use of cannabis, and over a dozen other countries have legalized cannabis-based products (CBD, Sativex, Dronabinol, etc.) for medical use. While there exists a plethora of anecdotal reports indicating that cannabis can treat a variety of diseases, there is a limited amount of strong, evidence-based scientific data to support these claims. This Special Edition of Biomedicines, “Therapeutic Potential for Cannabis and Cannabinoids”, was dedicated to providing evidence for the medicinal value of cannabis to treat human illness and disease. Topics included, but were not limited to, preclinical animal models examining the efficacy of cannabis and cannabinoid derivatives on pain, anxiety, cancer, and other diseases; and cell and molecular models of cannabinoid pharmacokinetics, drug–drug interactions, and disease treatment. These studies are of great importance not only for progressing the cannabis field, but also for validating the use of cannabis and cannabinoids as therapeutics.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 21 times via unglue.it ebook links.
- 21 - pdf (CC BY) at Unglue.it.
Keywords
- 2-hydroxy oleic acid
- age-related diseases
- Aging
- anandamide
- animal model
- anti Bcl2
- anti-biofilm activity
- anti-microbial activity
- Anxiety
- Apoptosis
- Autism Spectrum Disorder
- BDNF
- bile acids
- biosynthesis
- Calcium
- cannabidiol
- cannabidiol (CBD)
- cannabinoid
- cannabinoid receptors
- Cannabinoids
- Cannabis
- Cannabis sativa L.
- Cardiovascular Disease
- CB1 receptor
- CBD
- cell proliferation
- Child psychiatry
- chronic liver diseases
- Chronic Pain
- clinical trials
- cognitive dysfunction
- cortisol
- Cytokines
- D9 tetrahydrocannabinol
- developmental disorders
- elderly
- endocannabinoid system
- Endocannabinoids
- entourage effect
- Epilepsy
- estrogen deficiency
- FAAH inhibitors
- fatty acid amide hydrolase (FAAH)
- Ghrelin
- GHSR signaling
- Glucose
- Gut Microbiota
- gut organoids
- H9c2 cells
- HIV
- HRQoL
- hypoxia–ischemia
- immune
- Inflammation
- inflammatory bowel disease
- inhalation
- injury
- late adolescence
- macrophage
- medical cannabis
- medicine
- membrane lipid therapy
- MGL inhibitors
- mGluR5
- MMP-2
- MMP-9
- N-arachidonoylethanolamine
- n/a
- neonatal brain injury
- Neuroblastoma
- Neurogenesis
- neuropathic pain
- Neuroprotection
- Nitric Oxide
- ovariectomized mice
- pathogens
- PBMC
- phytocannabinoids
- phytochemistry
- pilot clinical trial
- polypharmacy
- post-traumatic stress disorder (PTSD)
- postmenopause
- Prefrontal Cortex
- Quality of life
- randomized controlled
- rat
- Rheumatoid arthritis
- Sleep
- Striatum
- synergy
- synovial fibroblast
- terpenes
- tetrahydrocannabinol
- tetrahydrocannabinol (THC)
- THC
- Transcriptomics
- TRPA1
- URB597
- VSMC
- Zebrafish
- β-catenin
- ∆9-tetrahydrocannabinol
Links
DOI: 10.3390/books978-3-0365-7583-4Editions